中国组织工程研究
中國組織工程研究
중국조직공정연구
Journal of Clinical Rehabilitative Tissue Engineering Research
2014年
5期
773-778
,共6页
实验动物%组织构建%胰岛移植%抗体药物偶联物%免疫抑制剂%免疫毒素%移植物排斥%抗体%肿瘤%国家自然科学基金
實驗動物%組織構建%胰島移植%抗體藥物偶聯物%免疫抑製劑%免疫毒素%移植物排斥%抗體%腫瘤%國傢自然科學基金
실험동물%조직구건%이도이식%항체약물우련물%면역억제제%면역독소%이식물배척%항체%종류%국가자연과학기금
islet transplantation%immunosuppressive agents%immunotoxins%graft rejection
背景：宿主与移植物间的免疫排斥反应是器官移植失败的主要原因之一，传统的免疫抑制剂已无法满足临床治疗的需求，抗体药物偶联物作为一类新型药物，可能为免疫排斥反应的治疗带来希望。<br> 目的：综合分析抗体药物偶联物的构成、作用机制、临床研究进展以及未来的发展趋势。<br> 方法：以“抗体药物偶联物、免疫抑制剂、免疫毒素、器官移植、移植物排斥”，“ADCs，immunosuppressive agents，immunotoxins，organ transplantation，graft rejection”为检索词，应用计算机检索CNKI 和 PubMed数据库。同一领域文献选择近期发表或发表在权威杂志文章，排除与研究目的无关和内容重复者，保留43篇文献做进一步分析。<br> 结果与结论：抗体药物偶联物以其高效低毒的特性在靶向治疗肿瘤方面已取得突破性进展，而在抗免疫排斥反应中仍处于摸索阶段。以同种胰岛移植为研究对象，寻找一种更有效阻断 CD8效应 T 细胞CD103/E-Cadherin通路的抗体药物偶联物，将可能成为同种器官移植抗排斥反应的新颖研究药物。
揹景：宿主與移植物間的免疫排斥反應是器官移植失敗的主要原因之一，傳統的免疫抑製劑已無法滿足臨床治療的需求，抗體藥物偶聯物作為一類新型藥物，可能為免疫排斥反應的治療帶來希望。<br> 目的：綜閤分析抗體藥物偶聯物的構成、作用機製、臨床研究進展以及未來的髮展趨勢。<br> 方法：以“抗體藥物偶聯物、免疫抑製劑、免疫毒素、器官移植、移植物排斥”，“ADCs，immunosuppressive agents，immunotoxins，organ transplantation，graft rejection”為檢索詞，應用計算機檢索CNKI 和 PubMed數據庫。同一領域文獻選擇近期髮錶或髮錶在權威雜誌文章，排除與研究目的無關和內容重複者，保留43篇文獻做進一步分析。<br> 結果與結論：抗體藥物偶聯物以其高效低毒的特性在靶嚮治療腫瘤方麵已取得突破性進展，而在抗免疫排斥反應中仍處于摸索階段。以同種胰島移植為研究對象，尋找一種更有效阻斷 CD8效應 T 細胞CD103/E-Cadherin通路的抗體藥物偶聯物，將可能成為同種器官移植抗排斥反應的新穎研究藥物。
배경：숙주여이식물간적면역배척반응시기관이식실패적주요원인지일，전통적면역억제제이무법만족림상치료적수구，항체약물우련물작위일류신형약물，가능위면역배척반응적치료대래희망。<br> 목적：종합분석항체약물우련물적구성、작용궤제、림상연구진전이급미래적발전추세。<br> 방법：이“항체약물우련물、면역억제제、면역독소、기관이식、이식물배척”，“ADCs，immunosuppressive agents，immunotoxins，organ transplantation，graft rejection”위검색사，응용계산궤검색CNKI 화 PubMed수거고。동일영역문헌선택근기발표혹발표재권위잡지문장，배제여연구목적무관화내용중복자，보류43편문헌주진일보분석。<br> 결과여결론：항체약물우련물이기고효저독적특성재파향치료종류방면이취득돌파성진전，이재항면역배척반응중잉처우모색계단。이동충이도이식위연구대상，심조일충경유효조단 CD8효응 T 세포CD103/E-Cadherin통로적항체약물우련물，장가능성위동충기관이식항배척반응적신영연구약물。
BACKGROUND:The immunological rejection between host and graft is the leading cause of organ <br> transplantation failure. The traditional immunosuppressive agents have been unable to meet the needs of clinical treatment. Antibody-drug conjugate, as a type of new drugs, may be hope for the treatment of immune rejection. OBJECTIVE:To comprehensively analyze the composition of antibody-drug conjugates, mechanism of action, clinical research progress as wel as the development trend. <br> METHODS:A computer-based online retrieval was performed to search papers in CNKI and PubMed database using the key words of ADCs, immunosuppressive agents, immunotoxins, organ transplantation, graft rejection in Chinese and English. Recently published or published in the prestigious journals were selected in the same field. After excluding objective-independent papers and repeated studies, 42 papers were included for further analysis. RESULTS AND CONCLUSION:Antibody-drug conjugates, as highly effective and lowly toxic immunosuppressant, have achieved a breakthrough in treatment of targeting tumor, while the role of it in anti-immune rejection is stil at the exploratory stage. For islet transplantation, novel antibody-drug conjugates are required to block CD8+T effector by CD103/E-Cadherin pathway, and wil probably serve as a potential drug intervention for al ograft rejection.
